Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4+ T Cells within Colorectal Tumors despite the Presence of Elevated CD39+ T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1 by Margaret R. Dunne et al.
March 2016 | Volume 6 | Article 501
Original research
published: 07 March 2016
doi: 10.3389/fonc.2016.00050
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Inti Zlobec, 
University of Bern, Switzerland
Reviewed by: 
Giandomenica Iezzi, 
University of Basel, Switzerland 
Marco Scarpa, 
Veneto Institute of Oncology, Italy
*Correspondence:
Elizabeth J. Ryan  
elizabeth.ryan@ucd.ie
†Elizabeth J. Ryan and Jean M. 
Fletcher contributed equally.
Specialty section: 
This article was submitted to 
Gastrointestinal Cancers, 
a section of the journal 
Frontiers in Oncology
Received: 28 October 2015
Accepted: 22 February 2016
Published: 07 March 2016
Citation: 
Dunne MR, Ryan C, Nolan B, 
Tosetto M, Geraghty R, Winter DC, 
O’Connell PR, Hyland JM, 
Doherty GA, Sheahan K, Ryan EJ 
and Fletcher JM (2016) Enrichment of 
Inflammatory IL-17 and TNF-α 
Secreting CD4+ T Cells within 
Colorectal Tumors despite the 
Presence of Elevated CD39+ T 
Regulatory Cells and Increased 
Expression of the Immune 
Checkpoint Molecule, PD-1. 
Front. Oncol. 6:50. 
doi: 10.3389/fonc.2016.00050
enrichment of inflammatory il-17 
and TnF-α secreting cD4+ T cells 
within colorectal Tumors despite the
Presence of elevated cD39+  
T regulatory cells and increased 
expression of the immune 
checkpoint Molecule, PD-1
 
Margaret R. Dunne1,2 , Ciara Ryan3 , Bláthnaid Nolan4,5 , Miriam Tosetto4,5 , Robert 
Geraghty3 , Des C. Winter4,5 , P. Ronan O’Connell4,5 , John M. Hyland4,5 , Glen A. Doherty4,5 , 
Kieran Sheahan3,4,5 , Elizabeth J. Ryan4,5*† and Jean M. Fletcher1,2†
1 School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 
2 School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 3 Department of Pathology,  
St. Vincent’s University Hospital, Dublin, Ireland, 4 Centre for Colorectal Disease, Education and Research Centre,  
St. Vincent’s University Hospital, Dublin, Ireland, 5 School of Medicine, University College Dublin, Dublin, Ireland
T cell infiltration into colorectal tumors has been shown to correlate with improved 
patient outcomes. However, more detailed information on the makeup and relationships 
between the infiltrating T cell subsets is lacking. We therefore correlated the extent of 
immune infiltration into colorectal tumors with the frequencies of various T cell subsets. 
We prospectively recruited 22 patients at the time of surgical resection for colorectal 
cancer. The Klintrup–Mäkinen (KM) score was used to estimate the extent of immune 
infiltration into colorectal tumors. The frequencies of CD4 and CD8 T cells that pro-
duced cytokines or expressed the inhibitory molecule programed cell death 1 (PD-1) 
were determined by flow cytometry in colorectal tumor and matched uninvolved colonic 
tissue. In addition, the frequency of CD4 regulatory T cell (Treg) subsets was determined. 
An increased frequency of CD4 T cells producing IL-17 (Th17 cells) was observed in 
colorectal tumor tissue compared with adjacent uninvolved tissue. These Th17 cells 
mostly coproduced TNF-α, but not IFN-γ. IL-17 expression correlated positively with 
TNF-α and IL-10. Increased expression of the immune checkpoint molecule PD-1 was 
found in colorectal tumors compared with adjacent uninvolved tissue. There was a 
negative correlation between expression of PD-1 and IFN-γ, but not IL-17, for both 
CD4+ and CD8+ T cells. CD4+CD25+CD127lo and CD4+CD25+CD127loFoxP3+CD39+ 
Treg cells were enriched in colorectal tumors. A positive correlation between KM score 
Abbreviations: CRC, colorectal cancer; CTLA-4, cytotoxic T lymphocyte antigen 4; DMSO, dimethyl sulfoxide; EMVI, extra-
mural vascular invasion; FBS, fetal bovine serum; IL, interleukin; LVI, lymphovascular invasion; NI, neural invasion; PBMC, 
peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PD-1, programed cell death 1; PENSTREP, penicillin 
streptomycin; PMA, phorbol myristate acetate; TNM, tumor node metastasis; Treg cell, regulatory T cell.
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inTrODUcTiOn
There is accumulating evidence indicating that the number, type, 
and location of tumor infiltrating lymphocytes has prognostic 
value in colorectal cancer (CRC), where robust T cell infiltration 
correlates with improved outcome (1, 2). These data have led to 
the development of the immunoscore, derived from measure-
ment of memory (CD45RO) CD3 and CD8 T cell infiltration into 
the tumor center, and invasive margin. Significantly, the immu-
noscore correlated positively with improved outcome regardless 
of stage and is being validated in large scale studies (3).
However, tumor infiltrating T cells contain a number of 
different functional subtypes, which can have either pro- or 
antitumor effects. Cytotoxic IFN-γ-producing CD8 T cells play 
a key role in the antitumor response. The role of CD4 T cells, 
which can be divided into Th1, Th2, Th17, and regulatory T cell 
(Treg) cell subsets, is more complex. Th1 cells, which produce 
IFN-γ and provide help to CD8 T cells, are considered to have 
an antitumor role (4). However, the role of Th17 cells in tumor 
immunity remains controversial. In the context of autoimmun-
ity Th17 cells are pro-inflammatory and pathogenic. Although 
studies in murine cancer models indicate an antitumor role 
for Th17 cells (5–7), there is contrasting evidence from other 
murine and human studies, suggesting that Th17 cells promote 
angiogenesis and drive tumor development (4, 8, 9). IL-17 
promotes angiogenesis by inducing VEGF production by tumor 
cells (9) and can mediate resistance to anti-VEGF therapy in 
murine models (10). Furthermore, the tumor microenviron-
ment promotes the recruitment and expansion of human Th17 
cells (11). Importantly, patients with low expression of Th17-
related genes exhibited prolonged disease-free survival (4). 
Thus on balance, the data from human studies appear to favor 
a model, where Th17 cells promote angiogenesis and tumor 
development.
Regulatory T cell cells play a crucial regulatory role in main-
taining tolerance and preventing autoimmunity. However, in 
the context of cancer, the general consensus is that Treg cells 
inhibit antitumor responses and contribute to the immunosup-
pressive microenvironment. However, it is possible that Treg 
cells could play a dual role by initially dampening protumor 
inflammation, but later acting to inhibit antitumor effector cells 
in the established tumor. In CRC, Treg cells have been shown to 
be enriched in the tumor (12); however, the role of these Treg 
cells remains controversial (13). In contrast to findings in other 
cancer settings, high levels of CRC tumor infiltrating Treg cells 
were associated with early stage disease and improved prognosis 
(14, 15). Other studies, however, did not find a positive correla-
tion between good prognosis and Treg cell infiltration (16, 17). 
The question of how tumor infiltrating Treg cells regulate local 
effector T cells within the tumor microenvironment remains to 
be determined.
The introduction of cancer immunotherapies, including 
those targeting CTLA-4 and programed cell death 1 (PD-1)/
PD-L1, has highlighted the therapeutic relevance of understand-
ing the regulation of local tumor immunity (18, 19). However, 
the success of immunotherapy is variable between patients and 
likely to be dependent on the presence of the relevant target; 
for example, the success of targeting the PD-1/PD-L1 axis was 
limited to patients with tumors expressing PD-L1 and with CD8 
T cell infiltration (20), and so far these drugs have demonstrated 
poor clinical efficacy in CRC (21). Here, we report a detailed 
analysis of tumor infiltrating Treg cells and PD-1+ lymphocytes 
in parallel with documenting the cytokine producing potential 
of effector cells within the same tumor. Interestingly, we found 
that despite being highly infiltrated by potentially immunosup-
pressive CD39+ Treg cells, colorectal tumors contain significant 
numbers of pro-inflammatory IL-17 and TNF-α secreting T 
cells. These effector T cells are likely to be a key component of 
the local tumor-sustaining inflammatory environment that is 
increasingly being recognized as a characteristic of solid tumors 
(22).
MaTerials anD MeThODs
Patient samples
Colorectal tumor and adjacent histologically normal tissue sam-
ples (at least 10 cm from tumor site) were obtained from 22 patients 
undergoing surgical resection at St. Vincent’s University Hospital, 
Dublin. Patient demographics and clinical details are reported in 
Table  1. Informed consent was obtained from all participants. 
Ethical approval for this study was granted by the St Vincent’s 
Healthcare Group Ethics and Medical Research Committee, and 
research was conducted according to the Helsinki guidelines.
histopathological analysis
The samples from surgical specimens were fixed in 10% buffered 
formalin solution and embedded in paraffin, and 5 mm sections 
were stained with H&E. We evaluated peritumoural inflammatory 
reaction from H&E slides according to the Klintrup–Mäkinen 
and percentage CD4+CD25+CD127lo Treg cells was observed in tumors, suggesting that 
increased immune infiltration is associated with an increased proportion of Treg cells. In 
addition, there was a negative correlation between the frequency of CD4+CD25+CD127lo 
Treg cells and the expression of IFN-γ and IL-2, but not IL-17, in tumors. Taken together, 
these data suggest that both PD-1 expressing T cells and Treg cells within the tumor 
may have a suppressive effect on T cells secreting IFN-γ, IL-2, or TNF-α, but not Th17 
cells.
Keywords: colorectal cancer, T cells, regulatory T cells, Th17 cells, PD-1, immunophenotyping, immunotherapy
TaBle 1 | Patient characteristics.
N 22
Male/female 16/6
Age (years), median 
(range)
69, 47–93
TMN stage Stage I (2), stage II (9), stage III (9), stage IV (2)
Lymphovascular 
invasion
Present (11), absent (11)
Perineural infiltration Present (6), absent (16)
Extramural venous 
invasion
Present (12), absent (10)
Mismatch repair loss 0/22
KM score 0 (2), 1 (16), 2 (4)
Tumor budding Present (10), absent (12)
Tumor differentiation Moderate (17), well (5)
Tumor size (cm), 
median (range)
4.8, 1.2–9.5
Tumor location Sigmoid (4), caecum (4), ascending (6), transverse (1), 
descending (3), rectal (4)
Surgery Curative intent (21), Hartman’s procedure (1)
Adjuvant chemotherapy 
recommended
Yes (10), no (12)
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(KM) criteria, where 0 denoted no recruitment of inflammatory 
cells; 1 denoted mild and patchy increase of inflammatory cells; 
2 denoted a band-like infiltrate at the invasive margin with some 
evidence of destruction of cancer cell islets; and 3 denoted a very 
prominent inflammatory reaction with frequent destruction of 
cancer cells. These scores were then classified into low grade (0–1) 
and high grade (2–3) (23, 24). All cases were also evaluated for the 
absence or presence of Crohn’s-like reaction (CLR).
cell isolation
Tissue samples were collected and transported in Hank’s Balanced 
Saline Solution, calcium- and magnesium-free (HBSS, Sigma-
Aldrich), supplemented with 1% FBS (Sigma) and PENSTREP, 
Gentamycin, and Fungizone (Labtech) (Life Technologies). 
Tissue fragments were washed thoroughly, chopped, digested in 
125 U/ml collagenase Type IV-S, and then sterile filtered (Sigma-
Aldrich) in HBSS. Tissue was incubated at 37°C with agitation, 
for no longer than 30  min. Cells were then filtered through a 
70-nm nylon mesh (BD Biosciences), washed in warm HBSS, 
and counted. Cells were either stained immediately for Treg cell 
markers and T cell memory markers or incubated overnight 
in complete RPMI medium (supplemented with 10% FBS and 
PENSTREP) prior to restimulation with PMA (10  ng/ml) and 
ionomycin (1 μg/ml) in the presence of brefeldin A (5 μg/ml) (all 
Sigma-Aldrich) for 3.5 h.
Flow cytometry staining
For analysis of PD-1, cells were washed in serum-free PBS and 
stained with a fixable viability dye, eFluor506, CD4-PerCPCy5.5, 
PD1-PECY7, CD8-APCeFluor780 (eBioscience), incubated 
for 15 min at room temperature in the dark, and then washed 
in PBS buffer containing 1% FBS and sodium azide. Cells were 
stained for Treg cell markers using a FoxP3 staining buffer set 
(eBioscience) and accompanying protocol. Treg cell markers 
included CD39-FITC, FoxP3-PE, CD73-PerCPeFluor710, CD25-
PECY7, CTLA-4-APC, CD127-APCeFluor780, Ki67-eFluor450 
(eBioscience), and CD4-V500 (BD Biosciences). An intracellular 
staining kit (Fix and Perm kit, Invitrogen) was used to analyze 
cytokine production after restimulation with PMA/ionomycin. 
Cells were stained with IL-17A-AlexaFluor488, IL-10-PE, TNF-
α-PerCPCy5.5, CD45RA-PECY7, CD8-APCeFluor780, FoxP3-
eFluor450 (all eBioSciences), CD45 AlexaFluor700 (BioLegend), 
IFN-γ-APC, CD3-V500, and IL-2-PE-CF594 (BD Biosciences). 
Due to PMA/ionomycin-mediated reduction in CD4 expression, 
CD4+ T cells were identified as CD3+CD8− T cells for cytokine 
analysis. Cells were acquired on a BD LSRFortessa flow cytometer 
and analyzed using FlowJo software (Flowjo LLC).
statistical analysis
Analysis of statistical differences in T cell population frequency 
and cytokine production between paired uninvolved tissue and 
tumor samples was performed using Prism GraphPad version 6. 
All data were assumed to be non-parametric and were analyzed 
using the Wilcoxon matched pairs test. Pearson’s correlation 
coefficient (r) was calculated using the Statistical Package for the 
Social Sciences (SPSS) version 18.0, IBM.
resUlTs
Varied grades of immune cell infiltration 
into colorectal Tumor Tissue
We prospectively recruited 22 patients at the time of surgical 
resection for CRC. Details of the patient cohort are shown in 
Table 1. All patients were treatment-naive at the time of surgery. 
Mismatch repair (MMR) status for all cases was determined by 
immunohistochemistry for the MMR proteins, MLH1, PMS2, 
MSH2, and MSH6. None of the tumors included in our analyses 
displayed microsatellite instability (MSI).
In this study, we used the KM score to estimate the extent of 
immune infiltration into colorectal tumors. After surgical resec-
tion, colorectal tumor tissue samples were paraffin embedded, 
sectioned, and H&E stained. Representative examples of KM 
scores 1–3 are shown in Figures 1A–C. Of the 22 cases examined, 
only n = 2 had a KM score of 0, indicating that the majority of 
MSS tumors included in this study were infiltrated by immune 
cells. We also documented the absence or presence of a CLR in 
all patient samples. An example of Crohn’s-like staining is shown 
in Figure 1D. Of the 22 tumors examined, 15 displayed evidence 
of a CLR, again indicating a significant degree of immune cell 
infiltration in the tumors of this cohort.
In addition, histologically normal adjacent tissue and tumor 
tissue were finely chopped and enzymatically digested to obtain 
single cell suspensions that were analyzed by flow cytometry 
to assess the phenotype of tumor infiltrating T cells. Cells were 
stained with antibodies specific for CD45 to identify tumor 
infiltrating leukocytes and panels of antibodies specific for T cell 
markers to identify specific subsets of T lymphocytes. Compared 
to uninvolved adjacent tissue, colorectal tumor tissue had an 
increased frequency of total T cells (p <  0.05) (CD3+ lympho-
cytes, Figure 1E). However, both the uninvolved normal tissue 
and colorectal tumor tissue were infiltrated by CD4+ and CD8+ T 
cells, with a CD4:CD8 ratio of approximately 2:1 (Figures 1F,G). 
FigUre 1 | colorectal tumors are highly infiltrated with T cells. Representative H&E slides of colorectal tumors with varying KM scores. (a) KM score 0,  
(B) KM score 1, (c) KM score 2, and (D) Crohn’s-like reaction. Single cell suspensions were also obtained by enzymatic digestion from surgically excised normal 
adjacent colonic tissue and colorectal tumors. The frequency of CD3+ (e), CD4+ (CD3+CD8−) (F), and CD8+ (g) T cells within lymphocytes was determined by flow 
cytometry. *p < 0.05 as determined by the Wilcoxon signed rank test.
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The vast majority of T cells infiltrating tumors were found to be of 
the effector memory type (data not shown). However, within the 
immune infiltrate, the ratio of CD4+:CD8+ T cells did not differ 
from uninvolved adjacent tissue.
increased Frequency of cD4+il-17+ (Th17) 
cells infiltrating colorectal Tumors
We then aimed to further dissect the phenotype and function 
of these colorectal tumor infiltrating lymphocytes by analyzing 
cytokine production by individual T cell subsets using intracel-
lular staining and flow cytometry. Single cell suspensions from 
normal adjacent tissue and colorectal tumor tissue were prepared 
from fresh surgical explants and stimulated for 3.5 h with PMA 
and ionomycin in the presence of brefeldin A. Cells were then 
stained with antibodies specific for T cell markers, permeabi-
lized, and incubated with antibodies specific for the following 
cytokines: IFN-γ, IL-17A, TNF-α, IL-2, and IL-10. No differences 
in the frequency of total CD3+, CD4+, or CD8+ T cells producing 
IFN-γ, TNF-α, IL-2, or IL-10 were observed between uninvolved 
intestinal tissue and tumor tissue (Figures 2A–C). There was a 
significant increase in the frequency of total CD3+ (p < 0.01) and 
CD4+ (p < 0.05) T cells producing IL-17 (Figures 2A,B), indicat-
ing that the local microenvironment of colorectal tumors can 
selectively enhance Th17 cell polarization or recruitment.
Tumor infiltrating Th17 cells coproduce 
TnF-α, but not iFn-γ
Having found significantly elevated frequencies of Th17 cells 
within the pool of lymphocytes recruited to colorectal tumors, 
we wished to further characterize this T cell subset. Th17 cells 
have been observed to exhibit plasticity of function and often 
coproduce IFN-γ, particularly at sites of inflammation. Cells that 
produce both IL-17 and IFN-γ are thought to be more pathogenic 
in inflammatory disease, but conversely would be more effective 
antitumor effectors. Therefore, we investigated if the tumor infil-
trating Th17 cells also produced other cytokines, notably IFN-γ 
FigUre 2 | increased frequency of cD4+il-17+ (Th17) cells infiltrating colorectal tumor tissue compared to normal adjacent tissue. Tumor tissue and 
adjacent uninvolved colonic tissue were enzymatically digested, and the resulting single cell suspension was stimulated with PMA and ionomycin. Cells were stained 
with antibodies specific for CD3 and CD8, permeabilized, and stained for intracellular expression of cytokines IFN-γ, IL-17, TNF, IL-2, and IL-10. The frequency of 
cytokine expressing total CD3+ (a), CD4+ (CD3+CD8−) (B), or CD8+ (c) T cells is shown for uninvolved colon and colorectal tumor tissue. *p < 0.05, **p < 0.01 as 
determined by Wilcoxon signed rank test.
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or TNF-α, as this would provide crucial information regarding 
their potential function.
Representative dot plots shown in Figure  3 were gated on 
tumor infiltrating CD4+ T cells and show IL-17 versus IFN-γ 
(Figure  3A), IL-17 versus TNF-α (Figure  3B), IL-17 versus 
IL-10 (Figure 3C), and TNF versus IFN-γ (Figure 3D) stain-
ing. There was no significant increase in the frequency of CD4+ 
T cells that coproduced IL-17 and IFN-γ (Figure 3E) or TNF 
and IFN-γ (Figure  3F). In addition, there was virtually no 
coexpression of IL-17 and IL-10 observed in tumor samples 
(Figure 3C). However, a significant increase in the frequency 
of IL-17+TNF-α+ CD4+ T cells was observed in tumor tissue 
relative to adjacent uninvolved intestine (p < 0.05) (Figure 3G). 
These data suggest that IL-17+TNF-α+CD4+ T cells may play a 
FigUre 3 | Th17 cells infiltrating colorectal tumors coexpress TnF-α, but not iFn-γ. Single cell suspensions that were obtained from tumor tissue and 
adjacent uninvolved colonic tissue were stimulated with PMA and ionomycin. Cells were stained with antibodies specific for CD3 and CD8, permeabilized, and 
stained for intracellular expression of the cytokines TNF-α, IFN-γ, and IL-17. Representative dot plots were gated on CD4+ (CD3+CD8−) T cells and show 
expression of IL-17 versus IFN-γ (a), IL-17 versus TNF-α (B), IL-17 versus IL-10 (c), or TNF versus IFN-γ (D). The frequencies of CD4+IL-17+IFN-γ+ (e), 
CD4+TNF+IFN-γ (F), or CD4+IL-17+TNF-α+ (g) T cells are shown for uninvolved colon and colorectal tumor tissue. *p < 0.05 as determined by the Wilcoxon signed 
rank test.
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role in shaping the local immune microenvironment of colo-
rectal tumors.
Consistent with the above data, a significant positive correlation 
between the frequencies of CD3+IL-17+ T cells and CD3+TNF-α+ 
T cells was observed (p < 0.05) (Table 2). In addition, a correla-
tion between expression of IL-17 and IL-10 within CD3+ T cells 
was found (p < 0.01) (Table 2); however, this did not appear due to 
coexpression of these cytokines. However, IFN-γ production by T 
cells correlated with the production of both TNF-α (p < 0.01) and 
IL-2 (p < 0.01) (Table 2). These data suggest that there are few IFN-
γ/IL-17 secreting T cells within colorectal tumors, with the majority 
of Th17 cells coproducing TNF-α. Furthermore, IFN-γ secreting T 
cells, when present, also secrete IL-2 in addition to TNF-α. Further 
understanding of the factors that contribute to these alternative 
cytokine profiles within the tumor infiltrating T cell pool is required.
increased expression of PD-1 on T cells 
within colorectal Tumors
Cytokine production is tightly regulated within human tissues 
by many mechanisms including cell–cell contact via the immune 
checkpoint, PD-1. Therefore, we investigated the expression of 
PD-1 on both CD4+ and CD8+ T cells in adjacent normal tissue 
and colorectal tumors by flow cytometry. Representative dot 
plots show staining controls in peripheral blood (Figures 4A,B) 
and PD-1 expression by colorectal tumor infiltrating CD4+ T 
cells (Figure 4B) or CD8+ T cells (Figure 4C). There was a sig-
nificantly increased expression of PD-1 on both CD4+ (p < 0.01) 
(Figure  4D) and CD8+ (p <  0.05) (Figure  4E) T cells within 
colorectal tumor tissue relative to adjacent uninvolved tissue. 
Interestingly, we found that there was a negative correlation 
between the expression of PD-1 and IFN-γ for both CD4+ and 
TaBle 2 | Pearson correlation of il-17 or iFn-γ production by tumor 
infiltrating cD3+ T lymphocytes versus other cytokines (n = 20).
Pearson correlation versus il-17+ lymphocytes
CD3+ IFN-γ 0.241
CD3+ TNF-α 0.519a
CD3+ IL-2 0.164
CD3+ IL-10 0.665b
Pearson correlation versus iFn-γ+ lymphocytes
CD3+ TNF-α 0.602b
CD3+ IL-2 0.747b
CD3+ IL-10 0.163
aCorrelation is significant at the 0.05 level (two-tailed).
bCorrelation is significant at the 0.01 level (two-tailed).
FigUre 4 | increased frequency of PD-1 expression on tumor 
infiltrating cD4+ and cD8+ T cells. Tumor tissue and adjacent uninvolved 
colonic tissue were digested and stained with antibodies specific for CD3, 
CD4, CD8, and PD-1. Representative FMO control (a) and PD-1 dot plots of 
PD-1 staining on CD3+ T cells in blood (B), PD-1 staining on CD4+ (B) and 
CD8+ (c) T cells in uninvolved colon or tumor samples are shown. The 
graphs show the frequency of PD-1+ CD4+ (D) and CD8+ (e) T cells. 
*p < 0.05, **p < 0.01 as determined by the Wilcoxon signed rank test.
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CD8+ T cells (p < 0.01) (Table 3). The expression of PD-1 on total 
CD3+ T cells also correlated negatively with CD4+IL-2+ (p < 0.05), 
CD8+IL-2+ (p  <  0.01), CD4+IFN-γ+TNF-α+ (p  <  0.01), and 
CD8+IFN-γ+TNF+ (p < 0.05) T cells (Table 3). In contrast, there 
was no correlation between the expression of PD-1 and IL-17, 
TNF-α, or IL-10 production (Table 3). These data suggest that 
the increased expression of PD-1 by colorectal tumor infiltrating 
lymphocytes may have a suppressive effect on both CD4+ and 
CD8+ effector T cells secreting IFN-γ, IL-2, or TNF-α, but not 
IL-17 within colorectal tumors.
increased Frequency of 
cD4+cD25+cD127lo and 
cD4+cD39+cD25+cD127loFOXP3+ Treg 
cells in colorectal Tumor Tissue
Regulatory T cell cells suppress effector T cells and are thought 
to contribute to the immunosuppressive microenvironment of 
tumors. Single cell suspensions obtained from both colorectal 
tumors and adjacent uninvolved tissue were stained for markers 
of Treg cells, including CD4, CD25, CD127, FOXP3, and CD39, 
and were analyzed by flow cytometry. The gating strategy for the 
identification of Treg cell populations is shown in Figure  5A. 
Lymphocytes were gated on the basis of CD45+ and forward 
scatter versus side scatter, and then CD4+ T cells were gated. A 
population of CD4+CD25+CD127lo Treg cells were identified, 
and then these were further gated on their expression of FOXP3 
to identify CD4+CD25+CD127loFOXP3+ Treg cells. The subset 
of Treg cells expressing CD39 was then identified (Figure 5A). 
An increased frequency of CD4+CD25+CD127lo Treg cells was 
identified in tumor tissue relative to adjacent colon (p <  0.05) 
(Figure 5B), while there was no significant difference in the fre-
quency of CD4+CD25+CD127loFOXP3+ Treg cells (Figure 5C). 
However, the frequency of CD39+ Treg cells was significantly 
increased in tumor tissue relative to uninvolved tissue (p < 0.05) 
(Figure 5D). A positive correlation between KM score and the 
percentage CD4+CD25+CD127lo Treg cells was observed in 
tumors (Table 4), suggesting that increased immune infiltration 
is associated with an increased frequency of Treg cells within the 
infiltrate. There was a negative correlation between the frequency 
of CD4+CD25+CD127lo Treg cells and the expression of IFN-γ 
and IL-2 in tumors (p < 0.05) (Table 4), suggesting that Treg cells 
may exert a suppressive effect on effector T cell cytokines.
DiscUssiOn
In this study, we investigated the phenotype of tumor infiltrating T 
cells by flow cytometry in a cohort of patients with MSS CRC whose 
tumors had broadly similar immune cell infiltrate as determined 
by pathological analysis (KM score). We found increased frequen-
cies of Treg cell populations in the colorectal tumor tissue, which 
positively correlated with the KM score. It has been established 
TaBle 3 | Pearson correlation of cD3+ T cell cytokine production with 
tumor infiltrating PD1+ T cells (n = 11).
cD3+ cytokine 
producing cells
Pearson correlation 
versus cD4+PD1+ T cells
Pearson correlation 
versus cD8+PD1+ T cells
IFN-γ −0.843b −0.952b
IL-17 −0.402 −0.426
TNF-α −0.632 −0.492
IL-10 −0.288 −0.149
IL-2 −0.642a −0.829b
IFN-γ+TNF-α −0.744b −0.626a
IFN-γ+IL-17 −0.298 −0.330
TNF-α+IL-17 −0.409 −0.368
aCorrelation is significant at the 0.05 level (two-tailed).
bCorrelation is significant at the 0.01 level (two-tailed).
FigUre 5 | increased frequency of cD4+cD25+cD127lo and cD4+cD25+cD127lo FoxP3+cD39+ Treg cells in colorectal tumor tissue. Tumor tissue and 
adjacent uninvolved colonic tissue were enzymatically digested to form a single cell suspension, which were stained with antibodies specific for CD45, CD4, CD25, 
CD127, FOXP3, and CD39, and were analyzed by flow cytometry to identify Treg cell populations. The sequential gating strategy used to identify Treg cell 
populations is shown in (a). The graphs show the frequency of CD4+CD25+CD127lo (B), CD4+CD25+CD127loFOXP3+ (c), and CD4+CD25+CD127loFOXP3+CD39+ 
(D) Treg cells. *p < 0.05, as determined by the Wilcoxon signed rank test.
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that increased immune infiltration is a positive prognostic factor 
in colorectal tumors. Our data showing a positive correlation 
between Treg infiltration and KM score therefore suggest that Treg 
cell infiltration may also correlate with improved outcomes. Given 
the prospective nature of our study, however, clinical outcomes 
were not yet available for our study cohort. Our findings are in 
broad agreement with others, which showed that increased Treg 
cell infiltration into colorectal tumors correlated with improved 
clinical outcomes (14, 15). This is in contrast to the case for the 
majority of other cancers, where Treg cell infiltration tends to be 
a negative prognostic indicator. Our findings and those of others 
showing Treg infiltration to be a positive prognostic factor seems 
counterintuitive, since it is generally assumed that Treg cells exert a 
pro-tumor role by suppressing antitumor immune responses. Treg 
cells have been shown to be enriched in parallel with effector T 
cells at inflamed peripheral sites within the body (25), most likely 
as an inherent mechanism to maintain homeostasis. However, for 
various reasons, Treg cells still fail to constrain inflammation at 
these sites of autoimmune inflammation (25). Colorectal tumors 
are known to be highly inflammatory relative to other tumor 
types (26). Thus, the enrichment of Treg cells within colorectal 
tumors may just be a reflection of the increased immune infiltra-
tion observed in colorectal tumors rather than an indication of a 
specific antitumor role for Treg cells.
Other studies did not find a positive correlation between good 
prognosis and Treg cell infiltration (16, 17). The reasons for these 
conflicting results are not clear. However, they may reflect some 
of the difficulties in identifying Treg cells by immunohistochem-
istry, since the use of sole Treg markers, such as CD25 or FoxP3, 
can lead to the false identification of activated effector T cells as 
Treg cells. In our study, using a flow cytometric approach, we were 
TaBle 4 | Pearson correlation of cD4+cD25+cD127+ T cells and 
infiltrating cytokine producing cells in colorectal tumors (n = 14).
Pearson correlation versus cD4+cD25+cD127+ T cells
KM score 0.518a
IL-17 −0.198
TNF-α −0.512
IFN-γ −0.574a
IL-2 −0.598a
IL-10 0.139
aCorrelation is significant at the 0.05 level (two-tailed).
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able to unequivocally identify Treg cells using a full panel of well 
accepted Treg markers. It is a matter of debate whether tumor 
infiltrating Treg cells act to inhibit antitumor effector T cells or 
other inflammatory responses, which may be proangiogenic, and 
thus protumorigenic (27).
We found that Tregs, which expressed the ectonucleotidase 
CD39, were enriched in colorectal tissue. CD39, which is nor-
mally expressed on a subset of human Treg cells in addition to 
other cells, acts to hydrolyze extracellular ATP to AMP, which is 
then further broken down to adenosine by CD73 (28). Adenosine 
binds to its cellular receptors, including the A2A receptor, on T 
cells where it exerts a suppressive effect. Thus, extracellular ATP, 
which is elevated in tumors, can be rapidly hydrolyzed by CD39 
expressing Treg cells to mediate suppressive effects on T cells. It 
is likely therefore that the CD39+ Tregs, which we identified in 
colorectal tumors, will have a suppressive effect via adenosine. 
We also observed an increase in CD25+CD127lo Treg cells, which 
were not all FoxP3+, although FoxP3+ Treg cells were included in 
this population. This was in agreement with a study that showed 
increased frequencies of FoxP3− Treg cells in colorectal tumors, 
which were even more suppressive than FoxP3+ Treg cells and 
produced IL-10 and TGF-β (29). The function of Treg cells within 
colorectal tumors is of key importance, particularly if they are to 
be considered as targets for immunotherapy. We, therefore, sought 
possible correlations between the frequencies of tumor infiltrat-
ing Tregs and T cell cytokines. The frequencies of CD25+CD127lo 
Treg cells correlated negatively with total T cell IFN-γ and IL-2, 
suggesting that these Treg cells may inhibit antitumor effector 
responses; however, there was no correlation between Treg cells 
and T cell IL-17 or TNF-α, both of which have been suggested to 
have pro-tumor activity (30, 31). Thus, it is possible that Treg cells 
are increased in colorectal tumors in proportion to the inflam-
matory infiltrate, where they may exert differentially suppressive 
effects on different subsets of T cells. The data suggest that Treg 
cells may be more effective at inhibiting T cells producing IFN-γ, 
such as Th1 and CTL, than those producing IL-17. Together with 
other immunosuppressive mechanisms within the tumor, this 
may help to tip the balance in favor of tumor progression.
Recent reports have described an aberrant subset of RORγt+/
FoxP3+ IL-17-producing Treg cells (32). We therefore investi-
gated whether the increased production of IL-17A by CD4 T cells 
within tumors was derived from FoxP3+ Treg cells. We saw that, 
although the majority of IL-17A in tumors came from FoxP3− CD4 
T cells, we also identified a population of IL-17+FoxP3+ CD4 T 
cells within tumors (data not shown). We also observed a positive 
correlation between IL-17 and IL-10 expression, although there 
was very little coexpression of these cytokines. The reason for 
the correlation between IL-17 and IL-10 expression is not clear; 
however, it has recently been shown that Th17 cells converted into 
IL-17−IL-10+ cells via a TGF-β-dependent mechanism (33). This 
may be a mechanism to downregulate inflammatory Th17 cells in 
the dynamic tumor environment.
In addition to Treg cells, the expression of PD-1 in tumors also 
provides important inhibitory signals in the tumor environment, 
where PD-1 expressing T cells can be rendered anergic by engag-
ing their ligand PDL-1, which is expressed on tumor cells (19). 
We observed increased expression of PD-1 on both CD4 and CD8 
T cells infiltrating colorectal tumors. PD-1 expression correlated 
negatively with T cell effector cytokines IFN-γ and IL-2, but not 
with IL-17. Increased expression of PD-1 on tumor infiltrating 
CD8 T cells correlated with an exhausted phenotype and reduced 
expression of IFN-γ and IL-2 (34). Thus, it appears that both Treg 
cells and PD-1 expressing cells may serve to inhibit effector T cells 
that produce IFN-γ and IL-2, but not IL-17, TNF-α, and IL-10. 
Since trials to test the efficacy of immune checkpoint inhibitors 
such as anti-PD-1 in CRC are ongoing, it will be crucial to under-
stand the role of PD-1 in colorectal tumors. There appear to be 
some discrepancies in the literature regarding the levels of PD-1 
expressed by tumor infiltrating lymphocytes, which are likely due 
to technical differences between studies. A study reporting that 
colorectal tumor infiltrating CD8+ T cells expressed little or no 
PD-1 employed a long (12-h) tissue digestion protocol (35), and 
this may have impacted on the phenotype of the recovered cells 
as determined by flow cytometry (36). In contrast, another study, 
which used a shorter digestion period, reported similar levels of 
PD-1 expression to those observed in our study (34). A further 
study investigating the expression of immune checkpoint inhibi-
tors in MSI versus MSS CRC demonstrated PD-1 expression on 
both CD4 and CD8 T cells (37). Although the levels of PD-1, in 
the latter study, appear lower than those that we observed, the 
PD-1 data were expressed relative to that of T cells infiltrating 
normal adjacent colon tissue (PD-1 high). Thus, the absolute 
expression levels of PD-1 on tumor infiltrating T cells appear 
very similar to those that we observed (37). These discrepancies 
highlight the need for harmonization of methods and validation 
of PD-1 expression levels among different patient cohorts.
IFN-γ produced by both CD8 and CD4 T cells is considered 
to be a key antitumor effector. However, we did not observe any 
global differences in the expression of IFN-γ by CD4 or CD8 T 
cells in tumor versus adjacent uninvolved tissue. IL-17A, which 
was increased in tumor tissue, was the only cytokine with altered 
expression when compared with adjacent uninvolved tissue. 
IL-17A was produced primarily by CD4 T cells, which largely 
coproduced TNF-α. In contrast, only a small proportion of IL-17+ 
cells coexpressed IFN-γ. Th17 cells are known to be plastic and 
polyfunctional in terms of cytokine production and in the context 
of autoimmunity coproduction of IL-17, and IFN-γ is thought 
to be inflammatory and pathogenic, while in tumors such cells 
might be good antitumor effectors. However, the role of Th17 cells 
in cancer is still controversial, with both pro- and antitumor roles 
having been ascribed to IL-17. In CRC, the consensus appears to 
be that the expression of IL-17 may be a negative prognostic factor 
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(4). Although IL-17 is an inflammatory cytokine that might be 
expected to have an antitumor effect, it is possible that its inflam-
matory effects rather serve to promote angiogenesis and promote 
tumor growth. Indeed, the angiogenic effects of IL-17 via the 
induction of VEGF have been documented (9). TNF-α also has 
angiogenic effects (30); thus, the Th17 cells that coproduce TNF-
α, but not IFN-γ, which we have identified as being enriched in 
colorectal tumor tissue, may be particularly effective at inducing 
angiogenesis and thereby promoting tumor growth. Our data 
suggest that these cells may not be constrained by the regula-
tory networks that are prevalent in the tumor, including CD39+ 
Treg cells and PD-1 expressing T cells. This may have important 
implications for tumor therapy, and a fuller understanding of the 
role of Th17 cells and their regulation within colorectal tumors 
is warranted. Furthermore, TNF-α and IL-17A are thought to 
have synergistic tumor promoting properties when expressed 
together in CRC cells, whereby these cytokines stimulate glucose 
metabolism and growth factor production (38).
aUThOr cOnTriBUTiOns
MD designed and performed flow cytometric analysis of 
tumor infiltrating and tissue T cell populations, analyzed data, 
contributed to the drafting of the manuscript, and approved the 
final version. CR and KS reviewed the pathology of all cases, 
performed the KM score analysis, contributed to the drafting of 
the manuscript, and approved the final version. BN, MT, RG, DW, 
PO, JH, and GD recruited and consented patients, provided clini-
cal samples, compiled and interpreted clinical information, and 
approved final manuscript. JF and ER designed the experiments, 
drafted the manuscript, and approved the final version and are 
accountable for the accuracy and integrity of the work.
FUnDing
This work was funded by a Science Foundation Ireland Starting 
Investigator Grant (BI593) to JF.
reFerences
1. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et  al. 
In situ cytotoxic and memory T cells predict outcome in patients with ear-
ly-stage colorectal cancer. J Clin Oncol (2009) 27(35):5944–51. doi:10.1200/
JCO.2008.19.6147 
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages 
C, et  al. Type, density, and location of immune cells within human col-
orectal tumors predict clinical outcome. Science (2006) 313(5795):1960–4. 
doi:10.1126/science.1129139 
3. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards 
the introduction of the ‘Immunoscore’ in the classification of malignant 
tumours. J Pathol (2014) 232(2):199–209. doi:10.1002/path.4287 
4. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. 
Clinical impact of different classes of infiltrating T cytotoxic and helper cells 
(Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res (2011) 
71(4):1263–71. doi:10.1158/0008-5472.CAN-10-2907 
5. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, 
et al. Th17 cells are long lived and retain a stem cell-like molecular signature. 
Immunity (2011) 35(6):972–85. doi:10.1016/j.immuni.2011.09.019 
6. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, et al. Human TH17 cells 
are long-lived effector memory cells. Sci Transl Med (2011) 3(104):104ra0. 
doi:10.1126/scitranslmed.3002949 
7. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. 
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. 
Immunity (2009) 31(5):787–98. doi:10.1016/j.immuni.2009.09.014 
8. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, 
et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 
in ovarian cancer in mice and humans. J Clin Invest (2009) 119(10):3011–23. 
doi:10.1172/JCI39065 
9. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with 
poor prognosis and promotes angiogenesis via stimulating VEGF production 
of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun (2011) 
407(2):348–54. doi:10.1016/j.bbrc.2011.03.021 
10. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, et al. An interleu-
kin-17-mediated paracrine network promotes tumor resistance to anti-angio-
genic therapy. Nat Med (2013) 19(9):1114–23. doi:10.1038/nm.3291 
11. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments 
direct the recruitment and expansion of human Th17 cells. J Immunol (2010) 
184(3):1630–41. doi:10.4049/jimmunol.0902813 
12. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, et al. Increased 
frequency of regulatory T cells in peripheral blood and tumour infiltrating 
lymphocytes in colorectal cancer patients. Cancer Immun (2007) 7:7. 
13. Zhuo C, Xu Y, Ying M, Li Q, Huang L, Li D, et al. FOXP3+ Tregs: heteroge-
neous phenotypes and conflicting impacts on survival outcomes in patients 
with colorectal cancer. Immunol Res (2015) 61(3):338–47. doi:10.1007/
s12026-014-8616-y 
14. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al. High fre-
quency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved 
survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 
(2010) 126(11):2635–43. doi:10.1002/ijc.24989 
15. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et  al. Tumor-
infiltrating FOXP3+ T regulatory cells show strong prognostic significance 
in colorectal cancer. J Clin Oncol (2009) 27(2):186–92. doi:10.1200/
JCO.2008.18.7229 
16. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et  al. 
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and 
prognosis: cohort study and literature review. J Pathol (2010) 222(4):350–66. 
doi:10.1002/path.2774 
17. Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, et al. Suppression 
of tumour-specific CD4(+) T cells by regulatory T cells is associated with pro-
gression of human colorectal cancer. Gut (2012) 61(8):1163–71. doi:10.1136/
gutjnl-2011-300970 
18. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 Blockade: new immu-
notherapeutic modalities with durable clinical benefit in melanoma patients. 
Clin Cancer Res (2013) 19(19):5300–9. doi:10.1158/1078-0432.CCR-13-0143 
19. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med (2015) 
373(16):1490–2. doi:10.1056/NEJMp1510079 
20. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, 
et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 
N Engl J Med (2012) 366(26):2443–54. doi:10.1056/NEJMoa1200690 
21. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 
blockade in tumors with mismatch-repair deficiency. N Engl J Med (2015) 
372(26):2509–20. doi:10.1056/NEJMoa1500596 
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
(2011) 144(5):646–74. doi:10.1016/j.cell.2011.02.013 
23. Klintrup K, Mäkinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, 
et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer (2005) 
41(17):2645–54. doi:10.1016/j.ejca.2005.07.017 
24. Vayrynen JP, Sajanti SA, Klintrup K, Makela J, Herzig KH, Karttunen TJ, et al. 
Characteristics and significance of colorectal cancer associated lymphoid 
reaction. Int J Cancer (2014) 134(9):2126–35. doi:10.1002/ijc.28533 
25. Basdeo SA, Moran B, Cluxton D, Canavan M, McCormick J, Connolly M, 
et  al. Polyfunctional, pathogenic CD161+ Th17 lineage cells are resistant 
to regulatory T cell-mediated suppression in the context of autoimmunity. 
J Immunol (2015) 195(2):528–40. doi:10.4049/jimmunol.1402990 
26. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. 
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-
mediated tumour growth. Nature (2012) 491(7423):254–8. doi:10.1038/
nature11465 
March 2016 | Volume 6 | Article 5011
Dunne et al. Th17 Cells Infiltrate Colorectal Tumours 
Frontiers in Oncology | www.frontiersin.org
27. Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating 
for or against tumor progression? Cancer Immunol Immunother (2014) 
63(1):67–72. doi:10.1007/s00262-013-1490-y 
28. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et  al. 
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory 
T cells mediates immune suppression. J Exp Med (2007) 204(6):1257–65. 
doi:10.1084/jem.20062512 
29. Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K, et al. Highly 
prevalent colorectal cancer-infiltrating LAP Foxp3 T cells exhibit more potent 
immunosuppressive activity than Foxp3 regulatory T cells. Mucosal Immunol 
(2013) 7(2):428–39. doi:10.1038/mi.2013.62  
30. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively  
V, Nuseir N. Macrophage-induced angiogenesis is mediated by 
tumour necrosis factor-alpha. Nature (1987) 329(6140):630–2. 
doi:10.1038/329630a0 
31. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et  al. 
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2003) 
101(7):2620–7. doi:10.1182/blood-2002-05-1461 
32. Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, Phillips JD, 
et al. Expression of RORgammat marks a pathogenic regulatory T cell subset 
in human colon cancer. Sci Transl Med (2012) 4(164):164ra59. doi:10.1126/
scitranslmed.3004566 
33. Gagliani N, Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, et al. Th17 
cells transdifferentiate into regulatory T cells during resolution of inflamma-
tion. Nature (2015) 523(7559):221–5. doi:10.1038/nature14452 
34. Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, et al. PD-1(+) CD8(+) T cells 
are exhausted in tumours and functional in draining lymph nodes of 
colorectal cancer patients. Br J Cancer (2014) 111(7):1391–9. doi:10.1038/
bjc.2014.416 
35. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical 
impact of programmed cell death ligand 1 expression in colorectal cancer. Eur 
J Cancer (2013) 49(9):2233–42. doi:10.1016/j.ejca.2013.02.015 
36. Abuzakouk M, Feighery C, O’Farrelly C. Collagenase and dispase enzymes dis-
rupt lymphocyte surface molecules. J Immunol Methods (1996) 194(2):211–6. 
doi:10.1016/0022-1759(96)00038-5 
37. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. 
The vigorous immune microenvironment of microsatellite instable colon 
cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 
(2015) 5(1):43–51. doi:10.1158/2159-8290.CD-14-0863 
38. Straus DS. TNFalpha and IL-17 cooperatively stimulate glucose metabolism 
and growth factor production in human colorectal cancer cells. Mol Cancer 
(2013) 12:78. doi:10.1186/1476-4598-12-78 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Dunne, Ryan, Nolan, Tosetto, Geraghty, Winter, O’Connell, Hyland, 
Doherty, Sheahan, Ryan and Fletcher. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s) 
or licensor are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
